Anti-anemia medication darbepoetin alfa no better than placebo for cancer patients Results from a phase III drug trial indicate that an anti-anemia drug did not significantly decrease the dependence on blood transfusions in individuals not on chemotherapy, and decreased general patient survival in comparison with placebo, according to researchers from the UCLA Medical Center at the 2007 Annual Meeting of the American Association for Cancers Research. The medication, darbepoetin alfa is definitely a synthetic form of erythropoietin, a hormone that indicators the formation of new red blood cells from within the bone marrow. DA is often used as a means of combating anemia in cancer tumor individuals who are also getting chemotherapy udenafila bula click here .
The Daily Health Policy Report is released for Kaisernetwork.org, a free support of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Board Business and Kaiser Family Basis. All rights reserved.. Annual Medicare report delayed to reflect impact of health law, the AP reports The Associated Press: The National government is delaying release of the annual record on the financial health of Sociable Security and Medicare so that the new report can reflect the impact of the recently passed healthcare overhaul. This content is usually republished with kind permission from our friends at The Kaiser Family Foundation.